Mirum Pharmaceuticals (NASDAQ:MIRM) Posts Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Mirum Pharmaceuticals (NASDAQ:MIRM) announced its earnings results on Wednesday. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.25), Yahoo Finance reports.

NASDAQ:MIRM traded down $0.20 during mid-day trading on Friday, reaching $6.88. The stock had a trading volume of 26,000 shares, compared to its average volume of 24,913. Mirum Pharmaceuticals has a 12 month low of $6.80 and a 12 month high of $15.50. The business has a 50-day simple moving average of $8.68.

A number of research analysts recently issued reports on the stock. Evercore ISI assumed coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued an “outperform” rating and a $25.00 price objective on the stock. Citigroup assumed coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued a “buy” rating and a $21.00 price objective on the stock. Raymond James assumed coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued an “outperform” rating and a $28.00 price objective on the stock. Roth Capital assumed coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Mirum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a research note on Wednesday, October 30th. Six equities research analysts have rated the stock with a buy rating, Mirum Pharmaceuticals currently has an average rating of “Buy” and an average price target of $22.25.

In related news, CEO Christopher Peetz purchased 9,070 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was purchased at an average cost of $11.02 per share, with a total value of $99,951.40. Also, Director Laurent Fischer purchased 4,650 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of $10.60 per share, with a total value of $49,290.00. Over the last ninety days, insiders acquired 21,432 shares of company stock valued at $232,684.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Recommended Story: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.